Skip to content

Svennilson Peter

Follow

13F filer, CIK 1606074, SAN FRANCISCO, CA

Svennilson Peter reported $837,452,000 across 5 holdings for the quarter ended 2019-12-31, in a 13F-HR filed 2020-02-12.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-20-001647

Period
2019-12-31
Reported value
$837M
Holdings
5
Top 10 weight
100%
New
1
Sold out
0

Stakes and trades reported after 2019-12-31

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • SRZN SURROZEN INC: 13D/A 3,813,501 shares, 18.2% of the class, 13D/A filed 2026-11-18, 0001193125-26-467393Timeline
    Accepted , ingested
  • TNYA TENAYA THERAPEUTICS INC: 13D/A 49,313,559 shares, 21.6% of the class, 13D/A filed 2026-11-16, 0001193125-26-463722Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
RAPT THERAPEUTICS INCnew+6,777,151$187M
NGM BIOPHARMACEUTICALS INCadded+253,922$4.7M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

None.

Holdings, Q4 2019

Share positions as resolved from 13F-HR 0000950123-20-001647, largest first. % of portfolio is the value over $837,452,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: not reported; 2019Q1: not reported; 2019Q2: 15,694,091 shares; 2019Q3: 16,166,907 shares; 2019Q4: 16,420,829 shares 16,420,829$304M36.26%+253,922
CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICALQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 4,677,938 shares; 2019Q1: 4,677,939 shares; 2019Q2: 4,677,939 shares; 2019Q3: 6,009,702 shares; 2019Q4: 6,009,702 shares 6,009,702$283M33.81%0
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: not reported; 2019Q1: not reported; 2019Q2: not reported; 2019Q3: not reported; 2019Q4: 6,777,151 shares 6,777,151$187M22.34%new
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 3,540,850 shares; 2019Q1: 3,540,850 shares; 2019Q2: 3,540,850 shares; 2019Q3: 3,540,850 shares; 2019Q4: 3,540,850 shares 3,540,850$35.8M4.27%0Timeline
GRITSTONE BIO INCGRITSTONE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2018Q1: restricted; 2018Q2: restricted; 2018Q3: restricted; 2018Q4: 3,102,934 shares; 2019Q1: 3,102,934 shares; 2019Q2: 3,102,934 shares; 2019Q3: 3,102,934 shares; 2019Q4: 3,102,934 shares 3,102,934$27.8M3.32%0

How Q4 2019 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-20-001647 base2020-02-12acceptance time not in the bulk data set